cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Heron Therapeutics Inc
13 own
30 watching
Current Price
$1.12
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
133.45M
52-Week High
52-Week High
5.62
52-Week Low
52-Week Low
1.07
Average Volume
Average Volume
1.8M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization133.45M
icon52-Week High5.62
icon52-Week Low1.07
iconAverage Volume1.8M
iconDividend Yield--
iconP/E Ratio--
What does the Heron Therapeutics Inc do?
Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the United States. Its drug delivery platform is designed to enhance the therapeutic profile of injectable pharmaceuticals. The company's lead product candidate includes SUSTOL (granisetron injection, extended release), which is in Phase III clinical trial for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. It is also developing HTX-011 that is in Phase I clinical trial for the management of post-operative pain; HTX-019, an injectable neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; and HTX-003, a formulation of buprenorphine for the management of chronic pain and opioid addiction. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.
Read More
How much money does Heron Therapeutics Inc make?
News & Events about Heron Therapeutics Inc.
PR Newswire
1month ago
Heron Therapeutics Announces Commercial Leadership Changes Heron Therapeutics Announces Commercial Leadership Changes PR Newswire SAN DIEGO, April 20, 2023 SAN DIEGO, April 20, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ('Heron'), a commercial-stage biotechnology company...
Fool.com Headlines
2 months ago
The stock has been rising since the company appointed a new CEO.Shares of Heron Therapeutics (NASDAQ: HRTX) were up more than 19% early Thursday afternoon. The biopharmaceutical company, which has been focusing on post-surgery therapeutics, has been on a steady rise since the company announced on ...
PR Newswire
2 months ago
Heron Therapeutics Announces New CEO and Board Chairman Heron Therapeutics Announces New CEO and Board Chairman PR Newswire SAN DIEGO, April 3, 2023 Craig Collard Appointed CEO Adam Morgan Named Chairman of the Board SAN DIEGO, April 3, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX...
PR Newswire
3 months ago
Heron Therapeutics Announces U.S. Commercial Launch of APONVIE for the Management of Postoperative Nausea and Vomiting in Adults Heron Therapeutics Announces U.S. Commercial Launch of APONVIE for the Management of Postoperative Nausea and Vomiting in Adults PR Newswire SAN DIEGO, March 6, 2023...
PR Newswire
4 months ago
Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises PR Newswire SAN DIEGO, Jan. 9, 2023 - Preliminary Annual Net Product Sales Across the Company Grew 24% to $106.7 Million in 2022...
Frequently Asked Questions
Frequently Asked Questions
What is Heron Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Heron Therapeutics Inc shares?
plus_minus_icon
How can I buy Heron Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Heron Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Heron Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Heron Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Heron Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Heron Therapeutics Inc?
plus_minus_icon
What percentage is Heron Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Heron Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.12
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
POSEIDA THERAPEUTICS INC
POSEIDA THERAPEUTICS INC
$2.55
$0.13 (5.37 %)
Athira Pharma Inc
Athira Pharma Inc
$3.01
$-0.01 (-0.33 %)
BioAtla Inc
BioAtla Inc
$3.57
$0.10 (2.88 %)
CHROMADEX CORP
CHROMADEX CORP
$1.56
$0.04 (2.63 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
POSEIDA THERAPEUTICS INC
POSEIDA THERAPEUTICS INC
$2.55
$0.13 (5.37 %)
Athira Pharma Inc
Athira Pharma Inc
$3.01
$-0.01 (-0.33 %)
BioAtla Inc
BioAtla Inc
$3.57
$0.10 (2.88 %)
CHROMADEX CORP
CHROMADEX CORP
$1.56
$0.04 (2.63 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00